Table 4.
Expression levels and clinical characteristics of patients with positive and negative fms-like tyrosine kinase 3/internal tandem duplications (FLT3/ITD+ and FLT3/ITD-) acute leukemia analyzed by reverse transcriptase-polymerase chain reaction and flow cytometry
| No. of patients |
|||
|---|---|---|---|
| Characteristic | FLT3/ITD+ AL | FLT3/ITD- AL | P |
| Age (years; median, range)* | 44 (21-70) | 47 (15-77) | 0.813‡ |
| Age >60 y | 6 | 29 | |
| Sex:* | 0.821‡ | ||
| male | 10 | 56 | |
| female | 9 | 45 | |
| Expression level of FLT3 mRNA† | 0.062 | 0.034 | 0.091§ |
| Surface expression level of FLT3 protein (%)* | 22.0 | 16.0 | 0.060§ |
| Peripheral blood white blood cell count ( × 109/L)* | 41.6 | 29.5 | 0.045§ |
| Blasts in the bone marrow (%)* | 79 | 56 | 0.014§ |
| Serum lactate dehydrogenase concentration (μ/L)* | 996.8 | 213.6 | <0.001§ |
| Outcome:* | 0.270‡ | ||
| complete remission | 14 | 85 | |
| failure | 5 | 16 | |
| complete remission rate | 73.7% | 84.2% | |
*19 FLT3/ITD- and 101 FLT3/ITD+ cases.
†12 FLT3/ITD- and 78 FLT3/ITD+ cases.
‡Fisher exact test.
§Mann-Whiney U test.